SGC-CBP30

SKU: orb1223263

Description

SGC-CBP30 is a potent and selective inhibitor of CREBBP (CBP) and EP300; which are general transcriptional co-activators. CREBBP has also been associated with Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig ’s disease, a neurodegenerative disease with progressive degeneration of motor neurons in the brain and spinal cord, Alzheimer's disease and poly glutamine repeat diseases such as Spinal and Bulbar Muscular Atrophy and Huntington ’s disease.

Key Properties

• CAS Number: 1613695-14-9
• MW: 509.04
• Purity: >98% (HPLC)
• Formula: C₂₈H₃₃CIN₄O₃
• SMILES: Cc1noc(C)c1c1cc2nc(CCc3ccc(OC)c(Cl)c3)n(C[C@H](C)N3CCOCC3)c2cc1
• Target: CREBBP| EP300
• Solubility: DMSO : ≥ 31 mg/mL; 60.90 mM

Bioactivity

• In Vivo:
  Animal model: Sprague-Dawley (SD) rats (aged 3-4 weeks) injected with NSC-125066. Dosage: 25 mg/kg. Administration: Oral administration; daily; for 14 days. Result: Slightly alleviated alveolar bronchial fibrosis induced by NSC-125066.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

SGC-CBP30 | SGC-CBP 30 | SGC-CBP-30

Quick Database Links

Gene Symbol

CREBBP| EP300